工业工程 ›› 2017, Vol. 20 ›› Issue (5): 38-44.doi: 10.3969/j.issn.1007-7375.e16-1276

• 专题论述 • 上一篇    下一篇

中国医药制造业技术创新系统协同演化分析

徐梦丹1,2, 朱桂龙1, 马文聪3   

  1. 1. 华南理工大学 工商管理学院, 广东 广州 510641;
    2. 广东药科大学 药学院, 广东 广州 510006;
    3. 广东工业大学 管理学院, 广东 广州 510520
  • 收稿日期:2016-10-12 出版日期:2017-10-30 发布日期:2017-11-17
  • 作者简介:徐梦丹(1980-),男,湖南省人,副教授,博士研究生,主要研究方向为技术创新管理.
  • 基金资助:
    国家自然科学基金项目(71233003,71403060);教育部哲学社会科学研究重大课题攻关项目(12JZD042);广东省软科学研究计划项目(2014A070703058,2013B070207008);广东省哲学社会科学“十二五”规划项目(GD14XGL42,GD13YGL04);广东省高等教育“创新强校工程”特色创新项目(2015GXJK060)

An Analysis on the Synergetic Evolution of Chinese Pharmaceutical Industry Technology Innovation System

XU Mengdan1,2, ZHU Guilong1, MA Wencong3   

  1. 1. School of Business Administration, South China University of Technology, Guangzhou 510641, China;
    2. School of Pharmay, Guangdong Pharmaceutical University, Guangzhou 510006, China;
    3. School of Management, Guangdong University of Technology, Guangzhou 510520, China
  • Received:2016-10-12 Online:2017-10-30 Published:2017-11-17

摘要: 为了解我国医药制造业技术创新系统的协同演化状态和规律,基于技术创新价值链和复杂系统论视角,将该系统解构为技术内部研发、技术外部获取、商业化、技术创新支撑环境等4个子系统,采用2007~2015年度统计年鉴数据,运用复合系统协同度模型对该系统演化的协同度及其各子系统的有序度进行测度和分析。结果表明,该系统的协同度及其各子系统的有序度随时间推移呈动态上升趋势,但其平均值较低;技术外部获取子系统是制约该系统向高水平协同发展的“短板”;不同序参量对其所属子系统有序度的影响权重不一;我国医药行业重大政策可能对系统协同发展产生明显的短期效应。最后,提出有针对性的政策建议。

关键词: 医药制造业, 技术创新系统, 协同度

Abstract: Based on the perspectives of technology innovation value chain and complex systems theory, the Chinese pharmaceutical industry technology innovation system can be deconstructed into four subsystems of internal technology R&D, external technology acquisition, commercialization and innovation supporting environment, to understand the evolution state and rule of this system. Using the data of statistical yearbook from 2007-2015 and the synergy degree model of composite system, this system's synergy degree and its subsystems' ordering degree in the evolution process are measured and analyzed. The results show that this system's overall synergy degree and its subsystems' ordering degree show a dynamically rising trend as time goes on but their average values are low; technology external acquisition subsystem is the restriction factor for the synergy development of the whole system to the high level; the influencing weights of different order parameters on their respective subsystems' ordering degree are different; the significant polices for China's pharmaceutical industry may produce a clear short-term effect on the system's synergy development. Finally, some policy recommendations are made based on the above conclusions.

Key words: pharmaceutical industry, technology innovation system, synergy degree

中图分类号: